the III course of intensive care in Pediatrics brings together future specialists in treatment of children with disorders acute.
– for a more realistic, real patients are used so that students can assess the diagnosis and treatment of each case in time real.
-the program has brought together 40 resident doctors in paediatrics of 4th year, who represent the next generation of managers of paediatric intensive care in Spain
Madrid, 2011-April already closed the course III of intensive care in paediatrics for resident ”, a program which annually brings together about 40 physicians representing all of the residents of Pediatrics of the 4th year that are sub-especializando on care intensive.
each year, the course focuses on a different theme. The program of this, which purports to be an immersion in acute respiratory diseases with more prevalence among pediatric patients, has been designed by SECIP (Spanish society of Pediatric and adult intensive care) with the collaboration of AstraZeneca.
to Dr. John Casado Flores, President of the SECIP and course Director, highlights of the program is teaching method. Real patients and an interactive method that allows you to participate in the diagnosis and treatment to all trainees are used. Each of these decides, therefore, as if you were patient, what exploration, treatment, or mechanical ventilation method used in each case ”.
throughout the program, which was held between 10 and 12 April, have been analysed 17 cases clinical of different typology. in addition, part of the afternoon on Monday took advantage to make the students formulate its own proposals for training of future on care intensive paediatric.
about AstraZeneca.
AstraZeneca is an innovative company biopharmaceutical global focused mainly on the discovery, development and commercialization of medicines prescribed for the areas of gastrointestinal, cardiovascular, neuroscience, respiratory, inflammation, oncology and infectious diseases. AstraZeneca operates in over 100 countries and their innovative medicines used by millions of patients around the world.
